Drug*placebo interaction effect may bias clinical trials interpretation: hybrid balanced placebo and randomized placebo-controlled design

被引:8
|
作者
Hammami, Muhammad M. [1 ,2 ]
Hammami, Safa [1 ]
Al-Swayeh, Reem [1 ]
Al-Gaai, Eman [1 ]
Farah, Faduma Abdi [1 ]
De Padua, Sophia J. S. [1 ]
机构
[1] King Faisal Specialist Hosp & Res Ctr, Dept Clin Studies & Empir Eth, POB 3354,MBC 03, Riyadh 11211, Saudi Arabia
[2] Alfaisal Univ, Coll Med, Riyadh, Saudi Arabia
来源
BMC MEDICAL RESEARCH METHODOLOGY | 2016年 / 16卷
关键词
Balanced placebo design; Randomized placebo-controlled trials; Biased drug effect size; Drug placebo interaction; Effect modification;
D O I
10.1186/s12874-016-0269-1
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Conventional randomized placebo-controlled study design assumes the absence of drug*placebo interaction. We hypothesized the presence of such an interaction and that conventionally estimated drug effect might be biased. The objectives of the study were to determine the drug*placebo interaction effect (main) and compare conventionally estimated and interaction model-estimated drug effects (secondary). Methods: We used a hybrid of balanced placebo and randomized placebo-controlled designs. Four hundred eighty healthy volunteers were randomized to three groups. The first received hydroxyzine (25 mg) described as hydroxyzine or placebo, the second received placebo described as hydroxyzine or placebo, and the third received hydroxyzine and placebo described as unknown; each in a randomized crossover design. Seven participants failed to crossover. Group assignment was concealed from participants and study coordinators. Coordinators were blinded to group and intervention assignment. Participants and coordinators were deceived as to study objectives. Main outcomes were mean area-under-the-curve of drowsiness (therapeutic outcome) and mouth-dryness (adverse outcome), self-reported on 100 mm visual analog scale over 7 h. Drug, placebo, placebo + interaction, and total effects were estimated using analysis of covariance by comparing received hydroxyzine/told placebo to received placebo/told placebo, received placebo/told hydroxyzine to received placebo/told placebo, received hydroxyzine/told hydroxyzine to received hydroxyzine/told placebo, and received hydroxyzine/told hydroxyzine to received placebo/told placebo, respectively. Drug effect was also conventionally estimated in the third group. Results: Mean (SD) age was 31.4 (6.6) years, 65% were males. There was significant difference between placebo + interaction effect and placebo effect for both drowsiness and mouth-dryness with a mean difference (95% confidence interval) of 35.1 (5.6 to 64.6) and 23.8 (2.4 to 45.2) mm*hr, respectively. Total effect was larger than the sum of drug and placebo effects for drowsiness (139.7 (109.8 to 169.6) vs. 99.1 (68.2 to 130.0) mm*hr) and mouth-dryness (63.6 (41.1 to 86.1) vs. 34.7 (11.1 to 58.4) mm*hr). Conventionally estimated drug effect was larger than interaction model-estimated drug effect for drowsiness (69.2 (45.5 to 92.8) vs. (58.3 (31.6 to 85.0) mm*hr) and mouth-dryness (19.9 (5.3 to 34.5) vs. 9.5 (-9.2 to 28.1) mm*hr). Conclusions: There is significant and important drug*placebo interaction effect that may bias conventionally estimated drug effect.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Drug*placebo interaction effect may bias clinical trials interpretation: hybrid balanced placebo and randomized placebo-controlled design
    Muhammad M. Hammami
    Safa Hammami
    Reem Al-Swayeh
    Eman Al-Gaai
    Faduma Abdi Farah
    Sophia J. S. De Padua
    BMC Medical Research Methodology, 16
  • [2] ASPECTS OF THE INTERPRETATION OF PLACEBO-CONTROLLED CLINICAL-TRIALS
    MULLER, AA
    BINZ, U
    WENDT, G
    PHARMACOPSYCHIATRY, 1985, 18 (01) : 127 - 128
  • [3] Randomized Placebo-Controlled Placebo Trial to Determine the Placebo Effect Size
    Gerdesmeyer, Ludger
    Klueter, Tim
    Rahlfs, Volker W.
    Al Muderis, Munjed
    Saxena, Amol
    Gollwitzer, Hans
    Harrasser, Norbert
    Stukenberg, Martin
    Prehn-Kristensen, Alexander
    PAIN PHYSICIAN, 2017, 20 (05) : 387 - 396
  • [4] Placebo response in placebo-controlled trials
    Cruz, N.
    Goikolea, J. M.
    Tohen, M.
    Baldessarini, R. J.
    Vieta, E.
    BIPOLAR DISORDERS, 2008, 10 : 73 - 73
  • [5] Randomised Controlled Trials May Underestimate Drug Effects: Balanced Placebo Trial Design
    Lund, Karen
    Vase, Lene
    Petersen, Gitte L.
    Jensen, Troels S.
    Finnerup, Nanna B.
    PLOS ONE, 2014, 9 (01):
  • [6] Patient expectations in placebo-controlled randomized clinical trials
    Stone, DA
    Kerr, CE
    Jacobson, E
    Conboy, LA
    Kaptchuk, TJ
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2005, 11 (01) : 77 - 84
  • [7] Review of Randomized Placebo-Controlled Trials
    Reito, Aleksi
    Karjalainen, Teemu
    Louhiala, Pekka
    ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY, 2020, 36 (11): : 2778 - 2779
  • [8] Placebo-controlled clinical trials: A reappraisal
    Bouvenot, G
    REVUE DU RHUMATISME, 1996, 63 (09): : 565 - 567
  • [9] Placebo effect-adjusted assessment of quality of life in placebo-controlled clinical trials
    Eickhoff, Jens C.
    STATISTICS IN MEDICINE, 2008, 27 (09) : 1387 - 1402
  • [10] Author Reply to "Placebo Trials in Orthopaedic Surgery" and "Review of Randomized Placebo-Controlled Trials"
    Sochacki, Kyle R.
    Dong, David
    Harris, Joshua D.
    Mather, Richard C.
    Nwachukwu, Benedict U.
    Nho, Shane J.
    Cote, Mark P.
    ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY, 2020, 36 (11): : 2779 - 2784